Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...
Drugging the Master Regulator TP53 in Cancer: Mission Possible? The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated ...
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
Study Finds on MSN
Scientists discover early gene change in pancreatic cancer
Much of pancreatic cancer’s evasive and deadly nature may come down to low levels of one gene. In A Nutshell Early detection, ...
Patients with TP53 germline variants have an increased risk of secondary sarcoma post-radiation therapy. The 15-year risk of sarcoma for TP53 pathogenic variant carriers is 8.8%, higher than the ...
Higgins is an advocate for people with Li-Fraumeni syndrome. I was born with an inherited cancer syndrome, Li-Fraumeni syndrome (LFS). A mutation on my Tp53 cancer suppressor gene makes me susceptible ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders ' lab have uncovered a sinister hidden mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results